AU2 94
Alternative Names: AU2-94; Oral CDK4 inhibitorLatest Information Update: 28 May 2025
At a glance
- Originator Aucentra Therapeutics
- Class Amines; Antineoplastics; Imidazoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Cancer in Australia (PO)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research
- 26 Jul 2021 AU2 94 is available for licensing as of 26 Jul 2021. https://www.aucentra.com/partners-investors/